GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nang Kuang Pharmaceutical Co 1752.TW · TWD

Health Care · Taiwan Stock Exchange · 🇹🇼 Taiwan

Compare

29.85

+0.17%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nang Kuang Pharmaceutical Co

Its shares trade on Taiwan Stock Exchange under the ticker 1752.TW. It has been listed since 10 June 2005. In the fiscal year to 31 December 2025, it reported revenue of TWD 2.16bn and net income of TWD 243.9m. At that date it held total assets of TWD 3.82bn and shareholders' equity of TWD 2.48bn.

Nang Kuang Pharmaceutical Co., Ltd. engages in the manufacture, process, and sale of western medicine and medical equipment. The company is headquartered in Tainan, Tainan. The company went IPO on 2005-06-10. The firm main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The firm is also engaged in the manufacture, processing and trading of medical equipment. The firm distributes its products within the domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
10 Jun 2005

Leadership

Pay as last reported

  • Mr. Lixian ChenChairman of the Board, Chief Strategy Officer, since 2005
  • Ms. Yu-bei WangGeneral Manager, Director, since 1973TWD 2.1m
  • Mr. Ben-sung ChenDeputy General Manager, Director, Corporate Governance Officer, since 2014
  • Mr. Ben-chung ChenDeputy General Manager
  • Lee-jen LaiHead of Accounting
  • Mr. Qicai LiaoHead of Finance
  • Mr. Zhilong LinDirector
  • Mr. Erh-Lang SuIndependent Director
  • Mr. Zhaoqin WangIndependent Director
  • Mr. Huangyuan WuIndependent Director
  • Mr. Boren ZhangIndependent Director
  • Ms. Guei-fen WangIR Contact Officer, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Tainan, Taiwan
  • Offers a diverse product range including injections and medical equipment
  • Operates both domestic and international markets

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No information on competitive advantages or unique selling points

Opportunities

  • Expansion into new international markets for pharmaceutical products
  • Growth potential in the domestic medical equipment sector
  • Potential for increased product diversification within pharmaceuticals

Threats

  • Competition from other pharmaceutical companies in Taiwan
  • Regulatory challenges in the pharmaceutical industry
  • Dependence on domestic market for a significant portion of revenue

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.